Newsroom Archive | Enterra Medical, Inc.

Newsroom

Enterra^® II System—an Advanced Treatment for Gastroparesis—Receives FDA Approval for MR Conditional Use

Enterra Medical, Inc., an innovator in treatments for people living with gastroparesis, announced today that the Enterra II System has been granted MR Conditional approval from the United States Food and Drug Administration (FDA).

MKT-D-0003, Rev X

IMPORTANT SAFETY INFORMATION

Enterra Therapy for treatment of chronic, resistant to medication nausea and vomiting associated with gastroparesis caused by diabetes or an unknown origin in patients aged 18 to 70 years: patients should always discuss potential risks and benefits of the device with their physician.

**^*HUMANITARIAN DEVICE**

Authorized by Federal law for use in the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years. The effectiveness of this device for this use has not been demonstrated. What does this mean?